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Pyruvate transport across the inner mitochondrial
membrane is believed to be a prerequisite for gluco-
neogenesis in hepatocytes, which is important for
themaintenance of normoglycemia during prolonged
food deprivation but also contributes to hyperglyce-
mia in diabetes. To determine the requirement for
mitochondrial pyruvate import in gluconeogenesis,
mice with liver-specific deletion of mitochondrial py-
ruvatecarrier 2 (LS-Mpc2/)weregenerated. Lossof
MPC2 impaired, but did not completely abolish, he-
patocyte conversion of labeled pyruvate to TCAcycle
intermediates and glucose. Unbiased metabolomic
analyses of livers from fasted LS-Mpc2/mice sug-
gested that alterations in amino acid metabolism,
including pyruvate-alanine cycling, might compen-
sate for the loss of MPC2. Indeed, inhibition of
pyruvate-alanine transamination further reduced
mitochondrial pyruvate metabolism and glucose
production by LS-Mpc2/ hepatocytes. These data
demonstrate an important role for MPC2 in con-
trolling hepatic gluconeogenesis and illuminate a
compensatory mechanism for circumventing a block
in mitochondrial pyruvate import.
INTRODUCTION
Hepatic glucose production is a critical physiologic process
that is required for maintaining normoglycemia during periods
of nutrient deprivation. However, under conditions of insulin defi-
ciency or resistance, hepatic glucose overproduction contrib-
utes to the hyperglycemia of diabetes. Metformin, which acts
in the liver to inhibit gluconeogenesis (Foretz et al., 2010), has
been used for years to lower blood glucose in type 2 diabetic
patients. There are three pathways for hepatic glucose produc-682 Cell Metabolism 22, 682–694, October 6, 2015 ª2015 Elsevier Intion: breakdown of glycogen (glycogenolysis), gluconeogenesis
from glycerol, and gluconeogenesis from lactate/pyruvate/
amino acids. Of these pathways, gluconeogenesis via pyru-
vate/lactate/amino acids predominates during prolonged food
deprivation (Burgess et al., 2006) and is deranged in the diabetic
liver (Satapati et al., 2012).
Pyruvate carboxylation to oxaloacetate is required for gluco-
neogenesis from pyruvate, and the enzyme that mediates this
reaction, pyruvate carboxylase, is exclusively localized to the
mitochondrial matrix. Therefore, it is believed that the transport
of pyruvate across the inner mitochondrial membrane is a
prerequisite step in gluconeogenesis from pyruvate/lactate.
The existence of carrier-assisted inner mitochondrial membrane
pyruvate transport has been known for many years, but the pro-
teins that facilitate pyruvate import into the mitochondrial matrix
have only been identified recently (Bricker et al., 2012; Herzig
et al., 2012). Our current understanding suggests that the
mammalian mitochondrial pyruvate carrier (MPC) is composed
of two proteins, MPC1 and MPC2, which form a hetero-oligo-
meric complex in the inner mitochondrial membrane, and that
both proteins are required for MPC complex activity and stability
(Bricker et al., 2012; Herzig et al., 2012). Indeed, deletion of either
MPC1 or MPC2 destabilizes the MPC complex and leads to the
loss of both proteins (Bricker et al., 2012; Colca et al., 2013; Her-
zig et al., 2012; Vigueira et al., 2014).
Despite the predicted importance of mitochondrial pyruvate
import in gluconeogenesis, little is known regarding the require-
ments for, and regulatory effects of, the MPC in this process.
Early work suggested that MPC activity was increased by
glucagon and inhibited by insulin (Titheradge and Coore,
1976a, 1976b), which would fit with the known effects of these
hormones on gluconeogenesis. Other studies using isolated liver
preparations showed an acute inhibition of hepatic glucose
output by chemical inhibitors of MPC activity, including a potent
inhibitor known as UK-5099 (Martin-Requero et al., 1986; Rogn-
stad, 1983; Thomas and Halestrap, 1981). Similarly, several
compounds containing thiazolidine rings, including the insulin-
sensitizing thiazolidinediones, bind and inhibit the MPC (Colca
et al., 2013; Divakaruni et al., 2013; Hildyard et al., 2005).c.
Thiazolidinediones (TZDs), which act canonically as ligands for
the nuclear receptor PPARg (Lehmann et al., 1995), have been
shown to suppress glucose production in perfused livers or iso-
lated hepatocytes within a matter of minutes (Adams et al., 1998;
Raman et al., 1998; Raman and Judd, 2000), suggesting a non-
genomic, acute, and direct hepatic effect of these compounds.
However, whether carrier-mediated pyruvate transport by
MPCs has significant control over gluconeogenesis has been
questioned in other studies using chemical inhibitors of MPCs
(Groen et al., 1983, 1986; Halestrap and Armston, 1984). Our
recent work in an MPC2 hypomorphic mouse model showed
that modest attenuation of MPC2 activity by genetic means did
not impair the flux of pyruvate into newly synthesized glucose
(Vigueira et al., 2014). Therefore, the influence of MPC2 on this
process remains unclear, and the data in hand suggest that
severe impairment of MPC activity may be needed to reduce
hepatic gluconeogenesis. Unfortunately, complete deletion of
MPC2 in a global manner is lethal at early embryonic stages (Vig-
ueira et al., 2014).
To circumvent the lethality associated with constitutive MPC
deletion and to address the role of mitochondrial pyruvate
import in liver intermediary metabolism, we generated mice
with liver-specific deletion of MPC2 (LS-Mpc2/mice) by using
the Cre-LoxP methodology. The initial characterization of
LS-Mpc2/ mice detected significant impairments in hepatic
mitochondrial pyruvate metabolism and gluconeogenesis that
were similar to mice with liver-specific deletion of the other pro-
tein of the MPC complex, MPC1 (Gray et al., 2015 [this issue of
Cell Metabolism]). However, we also determined that significant
gluconeogenesis and mitochondrial metabolism of pyruvate
occurred in hepatocytes with MPC2 deficiency, suggesting
that an alternative or circumventing pathway was compensating
for the loss of MPC activity. Metabolomic analyses suggested
that residual glucose production in LS-Mpc2/ livers may result
from altered amino acid metabolism. Indeed, mechanistic
studies demonstrated that pyruvate-alanine cycling can partially
compensate for the defect in mitochondrial pyruvate transport in
liver-specific MPC2 knockout mice. Together, these studies
confirm an important role for mitochondrial pyruvate transport
in hepatic gluconeogenesis but also unveil compensatory path-
ways that contribute to glucose production when MPC activity is
inhibited.
RESULTS
Generation of LS-Mpc2–/– Mice
Mice with liver-specific deletion of MPC2 (LS-Mpc2/ mice)
were generated using a conditional allele ofMpc2 (Figure 1A) as
described in the Experimental Procedures. LS-Mpc2/ mice
were viable and overtly indistinguishable from their littermate
control mice, which were also homozygous for the floxed allele
(fl/fl) but did not express Cre. LS-Mpc2/mice exhibited no dif-
ferences in bodyweight, liver weight, resting energy expenditure,
activity, or food or water intake (Figures S1A–S1C). qRT-PCR an-
alyses confirmed thatMpc2 mRNA was reduced dramatically in
LS-Mpc2/ liver compared with controls, whereas Mpc1 and
Mpc2 mRNA remained unaltered in the kidney and intestine,
consistent with liver-specificMpc2 deletion (Figure 1B). Western
blotting of isolated hepatocytes confirmed a loss of both MPC2Celland MPC1 proteins in LS-Mpc2/ liver (Figures 1C and 1D),
which is consistent with previous studies suggesting that both
proteins are required for MPC complex stability (Bricker et al.,
2012; Herzig et al., 2012; Vigueira et al., 2014).
Defective Hepatic Pyruvate Metabolism in
LS-Mpc2–/– Mice
Accumulation of 14C-pyruvic acid in mitochondria isolated from
LS-Mpc2/ livers was decreased markedly compared with
fl/fl liver mitochondria in a pyruvate transport assay (Figure 1E).
Permeabilized hepatocytes from LS-Mpc2/ mice also dis-
played a strong defect in pyruvate-stimulated, ADP-supported
oxygen consumption rate (OCR) compared with fl/fl controls,
whereas glutamate- and succinate-stimulated respiration re-
mained normal (Figure 1F). The mitochondrial membrane poten-
tial was unaffected in LS-Mpc2/ hepatocytes (Figure 1G),
possibly indicating that increased metabolism of other sub-
strates maintains mitochondrial viability and cellular homeosta-
sis. Accordingly, fatty acid oxidation was enhanced slightly but
significantly in LS-Mpc2/ hepatocytes compared with controls
(Figure 1H). Loss of the MPC also impaired the ADP-stimulated
OCR in isolated mitochondria when pyruvate was supplied as
a substrate (Figure 1I), but it did not affect maximal respiration
using glutamate or succinate as substrates (Figure 1J). Together,
these results suggest that loss of theMPC in hepatocytes results
in the expected decrease in mitochondrial pyruvate transport
and metabolism.
MSDC-0602 Alters Pyruvate Metabolism and Decreases
Glucose Production in an Mpc2-Dependent Manner
Using a 125I-radiolabeled photoaffinity probe, we discovered
recently that the MPC was bound directly by insulin-sensitizing
TZDs (Colca et al., 2013), including MSDC-0602, a novel
PPARg-sparing TZD currently in clinical trials (Colca et al.,
2014). Consistent with the specific binding of the TZD-based
probe to the MPC, photoaffinity crosslinking of a 14-kDa band,
which corresponds to the molecular weight of MPC2, was
lost completely in LS-Mpc2/ hepatocyte mitochondrial
membranes (Figure 1K). Unlabeled UK-5099 or MSDC-0602
effectively competed with 125I-labeled TZD crosslinking to the
14-kDa band, but not a non-specific band at 64 kDa, in fl/fl hepa-
tocytes (Figure 1K). Consistent with a direct effect on the MPC
and a competitive interaction with pyruvate, UK-5099 and
MSDC-0602 reduced the pyruvate-stimulated OCR in fl/fl liver
mitochondria but not in LS-Mpc2/ mitochondria (Figure 1I).
Given the predicted role for mitochondrial pyruvate import in
gluconeogenesis from pyruvate, we next evaluated glucose pro-
duction by hepatocytes with genetic or pharmacologic inhibition
of MPC activity. Isolated hepatocytes from LS-Mpc2/ mice
produced significantly less glucose compared with fl/fl hepato-
cytes when stimulated with pyruvate in vitro (Figure 2A). Chem-
ical inhibition of pyruvate import by UK-5099 orMSDC-0602 also
decreased glucose production in fl/fl hepatocytes but was
largely without effect on glucose production by LS-Mpc2/
hepatocytes (Figure 2A). To further assess pyruvate entry into
the mitochondria and carbon flux into tricarboxylic acid (TCA)
cycle intermediates and glucose, isolated hepatocytes were
cultured with 2.5 mM U-13C-pyruvate and 2.5 mM pyruvate,
and incorporation of 13C-labeled carbon into intracellular citrate,Metabolism 22, 682–694, October 6, 2015 ª2015 Elsevier Inc. 683
Figure 1. Generation and Characterization of LS-Mpc2–/– Mice
(A) Gene targeting strategy to delete exon 3 of Mpc2 in a liver-specific manner by Cre recombinase expressed under the control of the albumin promoter.
(B) Expression of Mpc1 and Mpc2 mRNA in the liver, kidney, and intestine in fl/fl and LS-Mpc2/ mice. AU, arbitrary unit.
(C) Representative western blot images for MPC2 and MPC1 protein in isolated hepatocytes.
(D) Quantification of MPC1 and MPC2 protein expression in isolated hepatocytes as in (C).
(E) Uptake of 14C-pyruvate by isolated mitochondria.
(F) ADP-supported oxygen consumption rates by isolated, permeabilized hepatocytes in the presence of the indicated substrates. WT, wild-type; Pyr, pyruvate;
Mal, malate; Glut, glutamate; Succ/Rote, succinate/rotenone.
(G) Mitochondrial membrane potential in LS-Mpc2/ and fl/fl hepatocytes as assessed by tetramethylrhodamine, ethyl ester, perchlorate (TMRE) staining.0
(H) Oxidation of 3H-palmitate in LS-Mpc2/ and fl/fl hepatocytes.
(I) Oxygen consumption rates of isolated mitochondria from fl/fl and LS-Mpc2/ livers stimulated by 5 mM pyruvate (P) and 2 mM malate (M) before and after
addition of 15 mM MSDC-0602 (602) or 10 mM UK-5099 (5099).
(J) Oxygen consumption rates of isolated mitochondria stimulated by 10 mM glutamate/2 mM malate or 5 mM succinate/0.5 mM rotenone.
(K) Photoaffinity crosslinking of an iodinated 125I-TZD photoprobe, MSDC-1101, specifically labels a 14-kDa protein in vehicle-treated (D, DMSO) fl/fl hepatocyte
mitochondrial membranes. Co-incubation with 30 mM unlabeled UK-5099 (U) or MSDC-0602 (M) prevented the labeling.
Data are presented as mean + SEM. *p% 0.05 for fl/fl versus LS-Mpc2/.
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Figure 2. Decreased Mitochondrial Pyruvate Metabolism and Glucose Production with Chemical or Genetic MPC Inhibition
(A) Glucose concentrations in themedia of cultured hepatocytes after stimulation by glucagon and 5mMpyruvate in the presence or absence of UK-5099 (2.5 mM)
or MSDC-0602 (15 mM).
(B–F) 13C-pyruvate flux into cellular (B) citrate, (C) succinate, (D) malate, (E) aspartate, or (F) medium glucose measured by mass spectrometry in fl/fl and
LS-Mpc2/ hepatocytes.
(G) Blood glucose concentrations after overnight fast and throughout a PTT. AUC, area under curve; KO, knockout.
(H) Blood lactate concentrations after overnight fast and throughout a PTT.
Data are presented as mean + SEM. *p% 0.05 versus vehicle-treated fl/fl hepatocytes.succinate, malate, and aspartate as well as media glucose was
measured by mass spectrometry. As predicted, loss of MPC2
led to a significant impairment in 13C incorporation into each of
these metabolites (Figures 2B–2F). Chemical inhibition of the
MPC with UK-5099 or MSDC-0602 also decreased 13C flux
into TCA cycle intermediates and glucose in fl/fl hepatocytes
but had little effect in LS-Mpc2/ hepatocytes (Figures 2B–
2F). Table S1 details the 13C enrichment and concentration of
a broad panel of intermediates from this study. These results, ob-
tained using genetic and pharmacologic approaches, strongly
suggest that mitochondrial pyruvate transport plays a role in
gluconeogenesis from pyruvate.CellDecreased Gluconeogenesis in LS-Mpc2–/– Mice
To determine the effects of liver MPC2 deletion on gluconeogen-
esis in vivo, we subjected LS-Mpc2/mice to an intraperitoneal
(i.p.) pyruvate tolerance test (PTT) after an overnight fast. Fasting
blood glucose concentrations at time 0 were significantly lower
in LS-Mpc2/ mice compared with fl/fl controls (Figure 2G).
Glucose concentrations were also lower in LS-Mpc2/ mice
compared with fl/fl controls at all times after bolus pyruvate in-
jection, consistent with impaired gluconeogenesis from pyruvate
(Figure 2G). LS-Mpc2/ mice were also observed to have
increased blood lactate concentrations compared with fl/fl con-
trols after fasting and throughout the PTT (Figure 2H). This couldMetabolism 22, 682–694, October 6, 2015 ª2015 Elsevier Inc. 685
be due to impaired lactate uptake by the liver or increased he-
patic lactate production. Importantly, the differences in blood
glucose concentration were not a result of altered glucose or
insulin tolerance because blood glucose concentrations were
similar during glucose tolerance tests (GTTs) (Figure S1D) and
insulin tolerance tests (ITTs) (Figure S1F). Blood lactate concen-
trations were found to be elevated in LS-Mpc2/ mice during
GTTs and ITTs (Figures S1E and S1G, respectively), again
consistent with impaired hepatic lactate metabolism.
Loss of the MPC in the Liver Leads to Protection from
Hyperglycemia
Hepatic gluconeogenesis is increased markedly in insulin defi-
ciency and contributes to the hyperglycemia of diabetes. We
rendered mice insulin-deficient with a single dose of 180 mg/g
streptozotocin (STZ), which reduced insulin concentrations simi-
larly in LS-Mpc2/ and fl/fl mice (Table S2). As expected, blood
glucose concentrations under ad libitum feeding conditions were
elevated significantly in STZ-treated animals compared with
saline vehicle control-treated mice within a few days of STZ
treatment (Figure 3A). However, compared with fl/fl mice, LS-
Mpc2/ mice had significantly lower blood glucose concentra-
tions after STZ injection (Figure 3A). Plasma-free fatty acids, total
ketone bodies, triglycerides, and cholesterol were all increased
by STZ treatment, but no significant differences between fl/fl
and LS-Mpc2/ mice were detected (Table S2). STZ-induced
insulin deficiency enhanced the expression of several gluconeo-
genic genes, including Mpc1 and Mpc2, in the liver, with no dif-
ferences between fl/fl and LS-Mpc2/ mice other than the loss
of Mpc2 (Figure 3B).
We also intercrossed mice harboring the floxed allele into the
db/db genetic background. Liver-specific deletion of Mpc2
markedly reduced blood glucose concentrations under ad
libitum feeding conditions in this model of genetic obesity and
diabetes (Figure 3C) without affecting body weight gain or fat
pad mass (Figures S2A–S2C). Loss of liver MPC activity also
did not affect liver weights or development of hepatic steatosis,
which was considerable in db/db mice (Figures S2D and S2E),
but did cause higher blood lactate levels (Figure S2F). Moreover,
loss of Mpc2 in the liver did not affect glucose tolerance
(Figure 3D), insulin tolerance (Figure 3E), or the transcriptional
activation of genes encoding gluconeogenic enzymes (Figure 3F)
in the livers of the db/db model, suggesting a specific effect on
hepatic glucose output rather than general insulin responsive-
ness. Together, these data suggest that hepatic mitochondrial
pyruvate import plays an important role in hepatic gluconeogen-
esis, which contributes to the hyperglycemia of diabetes.
Effect of 24-hr Food Deprivation on Liver Metabolism in
LS-Mpc2–/– Mice
Gluconeogenesis is a critical component of the hepatic response
to prolonged food deprivation. LS-Mpc2/ and fl/fl mice were
either given ad libitum access to a normal chow diet or subjected
to a 24-hr fast. As expected, the 24-hr fast lowered blood
glucose concentrations in both fl/fl and LS-Mpc2/mice. Blood
glucose concentrations in LS-Mpc2/ mice were slightly but
significantly, lower compared with fl/fl mice after 24 hr of fasting
(Figure 4A). Interestingly, LS-Mpc2/ mice displayed signifi-
cantly reduced liver glycogen in the fed state (Figure 4B),686 Cell Metabolism 22, 682–694, October 6, 2015 ª2015 Elsevier Inpossibly suggesting alterations in liver glycogen metabolism
to maintain normoglycemia or diminished synthesis of glycogen
from the indirect pathway, as detected in Pck1 knockout mice
(She et al., 2003). LS-Mpc2/ mice displayed elevated blood
lactate concentrations regardless of whether the mice were fed
ad libitum or fasted (Figure 4C). The effects of fasting on plasma
insulin, free fatty acid, and total ketone body concentrations
were not different between genotypes (Table S3). Fasting also
resulted in similar liver glycogen depletion (Figure 4B) and triacyl-
glycerol (TAG) accumulation (Table S3) in fl/fl and LS-Mpc2/
mice. Fasting modestly increased the hepatic expression of
Mpc1 and Mpc2 mRNA and protein in fl/fl mice (Figure 4D).
Loss of MPC2 did not impair the expression of genes encoding
gluconeogenic enzymes (Fbpase, G6pc, Pck1, and Pcx), which
was elevated significantly by fasting, and the livers of LS-
Mpc2/ mice exhibited a higher expression of Pck1 and Pcx
compared with fl/fl controls under fasted conditions and Pck1
under fed conditions (Figure 4D). LS-Mpc2/ mice also dis-
played elevated expression of some gluconeogenic enzymes
in the kidney compared with fl/fl mice (Figure 4E), perhaps sug-
gesting that glucose production from the kidneys may partially
compensate for the loss of MPC2 in the liver. These data suggest
that loss of theMPC in liver leads tomodest hypoglycemia under
fasting conditions without affecting other aspects of the hepatic
fasting response.
Metabolomic Profiling of the Fasting Response in LS-
Mpc2–/– Mice
Although fasted LS-Mpc2/mice were significantly hypoglyce-
mic compared with fl/fl controls, the magnitude of the effect of
MPCdeletion on glycemia was less thanwe expected. To screen
for potential hepatic compensatory mechanisms involved in the
maintenance of blood glucose levels, liver lysates from fasted
mice were analyzed by unbiased multiplatform metabolomics.
A total of 549 metabolites were measured, and when fl/fl and
LS-Mpc2/ livers were compared under the fasted condition,
33 metabolites were increased significantly (p < 0.05), and 60
metabolites were decreased significantly in LS-Mpc2/ livers
compared with fl/fl comparators (Table S4). Among the metabo-
lites that were altered, we detected an expected decrease in liver
glucose (p = 0.069; Figure 5A), glucose-6-phosphate (Figure 5B),
and fructose (Figure 5C) content in LS-Mpc2/ livers.
A pathway analysis of altered metabolites suggested effects
on several pathways in LS-Mpc2/ livers (Figure 5D), including
alterations in amino acid metabolism. Alanine, asparagine, and
aspartate (Figure 5E) and glutamate, glutamine, and a-ketogluta-
rate (Figure 5F) were all decreased significantly or tended to be
decreased in fasted LS-Mpc2/ liver compared with fl/fl liver.
This observation was interesting in light of the knowledge that
alanine and glutamine can be used as gluconeogenic substrates
and was the basis for the next series of studies.
Alanine Transamination Supports Gluconeogenesis in
LS-Mpc2–/– Mice
For alanine to be used for gluconeogenesis, it must be converted
to pyruvate. Alanine-pyruvate interconversion is catalyzed by
two alanine transaminase (ALT) enzymes that are expressed
robustly in liver (Figure 6A). ALT1 is localized to the cytosol,
and ALT2 is localized within the mitochondrial matrix (Yangc.
Figure 3. LS-Mpc2–/– Mice Are Protected from Hyperglycemia
(A) Blood glucose concentrations after induction of STZ-induced insulin deficiency in ad libitum-fed mice. Veh, vehicle.
(B) mRNA expression from livers of vehicle- or STZ-injected mice. Data are presented as mean + SEM. *p% 0.05 for fl/fl versus LS-Mpc2/. Ϯp% 0.05 for STZ
and vehicle.
(C) Blood glucose concentrations in ad libitum-fed fl/fl or LS-Mpc2/mice crossed into the db/db background. Data are presented asmean + SEM. *p% 0.05 for
fl/fl dbdb and LS-Mpc2/ dbdb. Ϯp% 0.05 for dbdb versus dbWT.
(D) Blood glucose concentrations during an i.p. glucose tolerance test.
(E) Blood glucose concentrations during an i.p. insulin tolerance test. Data are presented as mean + SEM. *p% 0.05 for fl/fl dbWT and LS-Mpc2/ dbWT at the
30-min time point.
(F) mRNA expression from livers of fl/fl or LS-Mpc2/ mice crossed into the db/db background. Data are presented as mean + SEM. *p% 0.05 for fl/fl versus
LS-Mpc2/. Ϯp% 0.05 for db/WT versus db/db.
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Figure 4. Fasting Response of LS-Mpc2–/– Mice
LS-Mpc2/ and fl/fl mice were either given ad libitum (ad lib) access to food or fasted 24 hr.
(A–C) Graphs depict (A) blood glucose concentration, (B) liver glycogen, and (C) blood lactate concentration.
(D) qRT-PCR analyses in livers from fed versus fasted fl/fl and LS-Mpc2/mice. Inset: western blot of liver lysates from fed and fastedmice, with quantification in
the text below the blot.
(E) qRT-PCR analyses of kidneys from fed versus fasted fl/fl and LS-Mpc2/ mice.
Data are presented as mean + SEM. *p% 0.05 for fl/fl versus LS-Mpc2/. Ϯp% 0.05 for fed versus fasted.et al., 2009). Previous reports of alanine transport into mitochon-
dria (Cybulski and Fisher, 1977; Dieterle et al., 1978) and alanine
transaminase localized to the mitochondrial matrix (ALT2) (Yang
et al., 2009) led us to hypothesize that there is an alternative route
of pyruvate carbon entry into mitochondrial pathways in LS-
Mpc2/ mice. Consistent with previous reports (Cybulski and
Fisher, 1977; Dieterle et al., 1978), uptake of radiolabeled alanine
was substantial in isolated liver mitochondria and was unaltered688 Cell Metabolism 22, 682–694, October 6, 2015 ª2015 Elsevier Inby Mpc2 deletion (Figure 6B). LS-Mpc2/ and fl/fl mice were
next subjected to bolus i.p. L-alanine injection in an alanine toler-
ance test (ATT). Blood glucose concentrations were significantly
lower in LS-Mpc2/ mice after the overnight fast, but blood
glucose increased similarly in both fl/fl and LS-Mpc2/ mice
by the 2-hr time point after alanine injection (Figure 6C).
To begin to investigate the role of pyruvate-alanine cycling
in the compensatory phenotype of LS-Mpc2/ mice, thec.
Figure 5. Metabolomic Analyses of Fasted fl/fl
and LS-Mpc2–/– Livers
(A–C) Liver (A) glucose, (B) glucose-6-phosphate
(G-6-P), and (C) fructose content in fasted LS-
Mpc2/ compared with fl/fl mice.
(D) Metabolic pathways that were most significantly
affected by genotype in fasted mouse liver.
(E and F) Alanine, asparagine, and aspartate content
(E) and glutamate, glutamine, and a-ketoglutarate
(aKG) content (F) in fasted LS-Mpc2/ and fl/fl livers.
Data are presented as box and whisker plots with
the negative error bar as the minimum of distribution,
the bottom of the box as the lower quartile, the line
bisecting the box as the median, the black square as
the mean, the top of the box as the upper quartile, and
the positive error bar as the maximum of distribution.
The numbers in parentheses are p values for fasted fl/fl
versus LS-Mpc2/ liver metabolite.expression of the genes (Gpt1 and Gpt2) encoding ALT1 and
ALT2 enzymes, respectively, were examined in liver. Gpt2,
but not Gpt1, was induced by fasting in mice but was not
affected by loss of Mpc2 (Figure 6D). However, in support of
increased transamination and the resulting urea production
in LS-Mpc2/ mice, liver citrulline and homocitrulline content
was elevated significantly compared with fl/fl control liver
(Table S4), which could suggest increased urea cycle activity.
We next knocked down liver Gpt2 expression in vivo by injec-
tion of an adenovirus expressing a short hairpin RNA (shRNA)
construct targeting Gpt2. Knockdown of Gpt2 mRNA by
55% in the liver had no effect on the blood glucose response
during a PTT in fl/fl mice but further reduced the glucose con-Cell Metabolism 22, 682–centration in LS-Mpc2/ mice (Figures
6E and 6F). These results indicate that
gluconeogenesis from alanine is unim-
paired in LS-Mpc2/ mice and that intra-
mitochondrial transamination of alanine to
pyruvate may contribute to gluconeogen-
esis when mitochondrial pyruvate import
is inhibited.
To further assess the possibility that
pyruvate-alanine transamination compen-
sates for diminished mitochondrial pyru-
vate import, isolated hepatocytes were as-
sessed for their ability to produce glucose
when stimulated with pyruvate
in conjunction with ALT inhibition. When
treated solely with glucagon, little glucose
was released into the media by hepa-
tocytes of any genotype. However, the
LS-Mpc2/ hepatocytes displayed signifi-
cantly lower glucose output under this
condition (Figure 7A), possibly because of
lower glycogen content (Figure 4B).
Glucagon supplemented with 5 mM pyru-
vate evoked an increase in glucose pro-
duction in both fl/fl and LS-Mpc2/
hepatocytes, but LS-Mpc2/ hepatocytes
produced significantly less glucosecompared with fl/fl hepatocytes, and this effect could be
mimicked by the MPC inhibitor UK-5099 in fl/fl hepatocytes
(Figure 7A). Incubation with amino-oxyacetate (AOA), an inhib-
itor of alanine transaminases (Gonza´lez et al., 2012), further
reduced the amount of glucose produced from pyruvate in
LS-Mpc2/ hepatocytes (Figure 7A). AOA treatment had no
effect on glucose produced from pyruvate in fl/fl hepatocytes
unless used in combination with the pyruvate transport inhibi-
tor UK-5099 (Figure 7A). These results strongly suggest that,
although mitochondrial pyruvate transport plays an important
role in gluconeogenesis, genetic or pharmacologic inhibition
of the MPC can be circumvented by an increased dependence
on pyruvate-alanine transamination.694, October 6, 2015 ª2015 Elsevier Inc. 689
Figure 6. Gluconeogenesis from Alanine Is
Normal in LS-Mpc2–/– Mice
(A) Schematic depicting the mitochondrial alanine
metabolism during defective mitochondrial pyru-
vate transport.
(B) Alanine uptake by isolated mitochondria from
fl/fl and LS-Mpc2/ livers.
(C) Blood glucose concentrations after i.p.
L-alanine injection during an ATT.
(D) qRT-PCR analyses for Gpt1 and Gpt2 in fed
versus fasted livers.
(E) Liver qRT-PCR analyses after injection of a
control adenovirus encoding an shRNA against
LacZ (Ad-shLacZ) or an adenovirus expressing an
shRNA against Gpt2 (Ad-shALT2).
(F) PTT analysis performed 5 days after in vivo
knockdown of ALT2.
Data are represented as mean ± SEM. *p % 0.05
for fl/fl versus LS-Mpc2/. Ϯp % 0.05 for fed
versus fasted or for Ad-shLacZ versus Ad-shALT2.Pyruvate Transport or Alanine Transamination Regulate
the Flux of Pyruvate Carbon into the TCA Cycle and
Glucose
Toconfirm thesefindings,weagainmeasured the incorporation of
the carbon contained in pyruvate into downstream intermediates
by using isolated hepatocytes cultured with 2.5 mM pyruvate
and 2.5mMU-13C-pyruvate andmass spectrometry. 13C-labeled
carbon incorporation into lactate was increased slightly in LS-
Mpc2/ hepatocytes compared with fl/fl controls (Figure 7B).
The hepatocyte content of pyruvate containing two labeled car-
bons [M2] (Figure 7C), which requires themitochondrial TCA cycle
metabolism to remove one labeled carbon, and [M3] TCA cycle in-
termediates (citrate, succinate, and malate; Figures 7D–7F)) were
reduced significantly in LS-Mpc2/ hepatocytes compared with
fl/fl controls. Importantly, loss ofMPC2also reduced [M3] glucose
concentration in the medium compared with fl/fl controls (Fig-690 Cell Metabolism 22, 682–694, October 6, 2015 ª2015 Elsevier Inc.ure 7G). AOA treatment of LS-Mpc2/ he-
patocytes further increased [M3] lactate
content and reduced 13C incorporation
into TCA cycle intermediates or medium
glucose (Figures 7B–7G). In contrast,
AOAwas largelywithout effect in fl/fl hepa-
tocytes (Figures 7B–7G), indicating that
transaminase activity is not essential for
pyruvate metabolism when the MPC is
intact. Table S5 details the 13C enrichment
andconcentrationofabroadpanel of inter-
mediates from this experiment. Together,
these pharmacologic and genetic data
provide strong evidence that the MPC is
required for full gluconeogenic capacity
but also suggest that pyruvate-alanine
cycling is an important alternative pathway
when MPC activity is impaired.
DISCUSSION
Hepatic glucose production from pyru-
vate/lactate is believed to be a criticalmetabolic function that prevents hypoglycemia under starved
conditions and is an important component of the Cori cycle.
Dogma dictates that gluconeogenesis from pyruvate and lactate
should require mitochondrial pyruvate import because the
synthesis of pyruvate from phosphoenolpyruvate (PEP) is not a
reversible reaction, and the carboxylase enzyme required for
the metabolism of pyruvate is only localized in the mitochondrial
matrix (Figure 6A). In this work, we show that MPC deletion in a
liver-specific manner has marked effects on gluconeogenic flux
and the mitochondrial intermediary metabolism of pyruvate.
Taken together with previous work, these data suggest that
mitochondrial pyruvate import is required for high rates of gluco-
neogenesis but also that the capacity for this process is likely
far in excess of that required for robust gluconeogenic flux and
that pathways to partially overcome MPC inhibition exist in
hepatocytes.
Figure 7. Pyruvate Transamination to
Alanine Compensates for Decreased Mito-
chondrial Pyruvate Transport in LS-Mpc2–/–
Hepatocytes
(A) Glucose production from pyruvate by LS-
Mpc2/ and fl/fl hepatocytes cultured in the
presence or absence of the alanine transaminase
inhibitor AOA(500 mM) and/or UK-5099.
(B–G) U13C-pyruvate flux into lysate (B) lactate, (C)
M2 pyruvate, (D) citrate, (E) succinate, (F) malate,
or (G) medium glucose as measured by mass
spectrometry using LS-Mpc2/ and fl/fl hepato-
cytes cultured in the presence or absence of AOA.
Data are expressed as mean + SEM. *p% 0.05 for
fl/fl versus LS-Mpc2/. Ϯp % 0.05 for vehicle
versus AOA.Although several studies have shown that chemical inhibition
of MPC activity decreases liver glucose production (Lima et al.,
2006; Martin-Requero et al., 1986; Rognstad, 1983; Thomas
and Halestrap, 1981), other studies using small molecule inhibi-
tors of the MPC (Rognstad, 1983) or hepatocytes expressing a
hypomorphic MPC2 allele (Vigueira et al., 2014) failed to demon-
strate a strong effect of MPC impairment on gluconeogenesis.
Our studies may explain a lack of effect of MPC inhibition onCell Metabolism 22, 682–69gluconeogenesis by elucidating a
compensatory pathway that is operant
when mitochondrial pyruvate flux is
impaired. Metabolomic profiling of fasted
LS-Mpc2/ liver tissue detected signifi-
cant reductions in the concentrations of
several amino acids related to the meta-
bolism of alanine and glutamine, which
can also be used as gluconeogenic sub-
strates. Although our paper focused on
pyruvate-alanine cycling, a companion
paper (Gray et al., 2015) clearly showed
adaptive use of glutamine to maintain
TCA cycle flux in MPC1-deficient liver.
We found modest changes in the expres-
sion of genes encoding enzymes of the
TCA cycle proximal to the entry of gluta-
mine/glutamate at a-ketoglutarate (Idh2
and Sdha) in livers of fasted MPC2-defi-
cient mice but no effect on enzymes
involved directly in glutaminolysis (Table
S3). It is likely that alterations in the meta-
bolism of glutamine and related amino
acids as well as altered alanine utilization
are all present in MPC2-deficient mice
because we detected a depletion of
glutamine, glutamate, and a-ketogluta-
rate. Given that the mitochondrial meta-
bolism of pyruvate is such an important
process in intermediary metabolism, it is
not unexpected that compensatory
adaptations would exist. Indeed, recent
work in cultured cells has shown that
enhanced use of these amino acids asTCA cycle substrates helps to allow cells to survive in the
context of MPC deficiency (Du et al., 2013; Vacanti et al.,
2014; Yang et al., 2014), and the present in vivo studies are
consistent with this.
Alanine can be transported across the inner mitochondrial
membrane by a carrier-mediated mechanism (Cybulski and
Fisher, 1977; Dieterle et al., 1978). The MPC does not mediate
this transport activity; we found that mitochondrial alanine4, October 6, 2015 ª2015 Elsevier Inc. 691
import and its stimulatory effects on gluconeogenesis were
unaffected by pharmacologic inhibition or genetic loss of
MPC2. Previous work has also shown that very high (millimolar)
concentrations of cinnamate MPC inhibitors did not markedly
affect hepatic glucose production from alanine (Groen et al.,
1982; Patel and Olson, 1985). Although alanine transamination
to pyruvate can occur in the cytosol (DeRosa and Swick,
1975), several previous studies have indicated an important
role for the mitochondrial alanine transaminase (ALT2) in gluco-
neogenesis from alanine by transaminating alanine to pyru-
vate in the mitochondrial matrix (DeRosa and Swick, 1975).
The data obtained with LS-Mpc2/ hepatocytes or UK-5099
in combination with AOA are also consistent with intramitochon-
drial alanine deamination.
Hepatic glucose overproduction contributes to hyperglycemia
in uncontrolled diabetes. Given the ability of MPC inhibition or
deletion to suppress gluconeogenesis from pyruvate/lactate
and prevent hyperglycemia, there may be utility in targeting the
MPC complex as a glucose-lowering strategy. Several cinna-
mate analogs (including UK-5099) (Halestrap, 1975) and thiazo-
lidine ring-containing compounds designed as KATP channel
agonists (Hildyard et al., 2005) and insulin-sensitizing thiazo-
lidinediones (troglitazone, rosiglitazone, pioglitazone, MSDC-
0160, and MSDC-0602) (Divakaruni et al., 2013) inhibit the
MPC. The PPARg-sparing TZDs MSDC-0602 and MSDC-0160
have been crosslinked specifically to the MPC complex in liver
mitochondria (Colca et al., 2013) and suppressed mitochondrial
pyruvate oxidation in cultured cells in an MPC-dependent
manner (Divakaruni et al., 2013). In this work, we show that
MSDC-0602 and UK-5099 suppress hepatocyte glucose pro-
duction, pyruvate-stimulated mitochondrial OCR, and 13C-pyru-
vate incorporation into TCA cycle intermediates or glucose via a
mechanism that requires the MPC, suggesting that, at least
in vitro, this effect of the drugs could be mediated by an interac-
tion with the MPC. This finding also provides an explanation and
mechanism for our previous observation that suppression of
glucose production by the novel TZDMSDC-0602 wasmediated
independently of PPARg because MSDC-0602 was able to sup-
press glucose production by hepatocytes from LS-PPARg/
mice (Chen et al., 2012). Whether interaction with the MPC is
required for the insulin-sensitizing effects of these PPARg-
sparing TZDs in vivo remains to be determined. Unfortunately,
this proof-of-concept study is complicated by the effects of
TZDs in multiple tissues and the fact that whole body MPC2
knockout in mice leads to embryonic lethality (Vigueira et al.,
2014).
In conclusion, we present evidence that liver-specific defi-
ciency in theMPC, which is a target for anti-diabetic drugs, leads
to impairments in hepatic gluconeogenesis in mice. Despite a
defect in gluconeogenesis from pyruvate, LS-Mpc2/ mice
are outwardly normal, display no evidence of overt liver pathol-
ogy, and exhibit only modest hypoglycemia during prolonged
fasting studies. We also demonstrate that pyruvate-alanine
cycling in LS-Mpc2/ mice likely constitutes an alternative
pathway for gluconeogenesis from pyruvate/lactate to proceed
by circumventing the MPC complex. Future work will be needed
to determine whether selectively targeting the MPC complex is a
viable strategy for treating diabetes and other associated meta-
bolic diseases.692 Cell Metabolism 22, 682–694, October 6, 2015 ª2015 Elsevier InEXPERIMENTAL PROCEDURES
Additional procedures can be found in the Supplemental Experimental
Procedures.
Animal Studies
All experiments were conducted with 6- to 12-week-old mice of both sexes. All
animal experiments were approved by the Animal Studies Committee of the
Washington University School of Medicine.
Generation of Mpc2 Flox and LS-Mpc2–/– Mice
C57/Bl6 mouse embryonic stem cells containing a ‘‘knockout first’’ allele of
Mpc2 were obtained from the European Conditional Mouse Mutagenesis
Program (EUCOMM) (International Knockout Mouse Consortium [IKMC] proj-
ect 89918, catalog no. MAE-1900). This construct contains a targeted allele of
Mpc2 containing inserted cassettes for promoter-driven LacZ and Neo cDNAs
flanked by frt sites upstream of exon 3 of the Mpc2 gene, which is flanked by
LoxP sites. Propagated ESCs were injected into developing embryos and then
implanted into pseudopregnant females. Chimeric offspring were mated to
establish germline transmission. Resulting heterozygous offspring weremated
with C57/Bl6 mice expressing Flp recombinase in a global manner (chicken a
actin promoter-driven transgenic) to remove the LacZ and Neo cassettes and
generate mice harboring the conditional floxed allele (Figure 1A).Mpc2 floxed
mice were then crossed with hemizygous C57/Bl6 mice expressing Cre under
the Albumin promoter to create LS-Mpc2/ mice. Littermate mice not
expressing Cre (fl/fl mice) were used as control mice in all experiments. For
db/db intercross experiments, C57/Bl6 Leprdb/+ mice were obtained from
The Jackson Laboratory and crossed with LS-Mpc2/ mice.
Phenomaster Metabolic Profiling
Indirect calorimetry, energy expenditure, spontaneous activity, and food/
water consumption were measured in Phenomaster TSE cages similarly as
reported previously (Tang et al., 2015). Data were measured and collected at
10-min intervals.
13C-Labeled Pyruvate Hepatocyte Studies
Primary adult hepatocytes were isolated and cultured as described previously
(Chen et al., 2008). Hepatocytes were isolated and cultured in 60-mm dishes
for 12 hr as described above. Hepatocytes were washed twice with PBS and
incubated in Hank’s balanced salt solution (HBSS) for 2 hr and then washed
with fresh HBSS. The hepatocytes were then incubated for 4 hr in HBSS con-
taining 2.5 mM U13C-labeled sodium pyruvate (Cambridge Isotope Lab) plus
2.5mMunlabeled sodiumpyruvate or 5mMunlabeled sodiumpyruvate (to cor-
rect for background enrichment) in combination with 10 mM UK-5099, 15 mM
MSDC-0602, or 500 mM AOA. Cell culture medium was removed and frozen,
and cells were washed with ice-cold PBS, fixed immediately in 20C 100%
methanol, scraped from the dishes, and frozen. Cell lysates and media were
analyzed by gas chromatography-mass spectrometry (GC-MS) or liquid chro-
matography-mass spectrometry (LC-MS) to determine 13C enrichment and
concentration as described previously for glucose (Sunny and Bequette,
2010), organic acids (Des Rosiers et al., 1994), and amino acids (Casetta
et al., 2000; Fu¨zfai et al., 2004). Data are reported as 13C enrichment 3
concentration.
TZD Photoaffinity Crosslinking
The iodinated (125I) photoprobe MSDC-1101 was used for photoaffinity cross-
linking of crude mitochondrial membranes from isolated fl/fl and LS-Mpc2/
hepatocytes as described previously (Colca et al., 2004, 2013). The addition of
cold UK-5099 or MSDC-0602 (30 mM) was used as competition for the MPC2
binding site prior to photoactivation.
Non-biased Comprehensive Metabolomic Analysis
Frozen liver chunks (100 mg) from ad libitum-fed or 24-hr fasted mice
were shipped frozen to Metabolon, extracted, and analyzed as described
previously (Hatori et al., 2012). Three independent platforms (ultrahigh per-
formance liquid chromatography/tandem mass spectrometry optimized for
basic species and acidic species and gas chromatography/mass spectrom-
etry) were utilized for biochemical detection. Metabolites were identified byc.
automated comparison of ion features in samples to a reference library
of chemical standards entries, including retention time, molecular weight
(m/z), preferred adducts, and in-source fragments as well as associated
MS spectra. Values below limits of detection were ascribed with compound
minimum. ANOVA of log-transformed data was performed to compare data
between groups. Multiple comparisons were accounted for by estimating
false discovery rates.
Adenoviral Construction and In Vivo Adenoviral Infection
Adenovirus expressing GFP reporter and a validated shRNA targeting murine
Gpt2 (glutamic pyruvate transaminase, also known as ALT2) was obtained
from Vector Laboratories (shADV-260703). An adenovirus-driven shRNA
construct targeting LacZ and the GFP reporter was used as a vector con-
trol (Finck et al., 2006). Mice were infected by retro-orbital injection of
150–200 ml high-titer adenoviruses.
Statistical Analyses
Statistical comparisons were made using Student’s t test or ANOVA where
appropriate. All data, unless specified otherwise, are presented as mean ±
SEM, with a statistically significant difference defined as p% 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and five tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cmet.2015.07.028.
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